Caseware UK (AP4) 2025.0.111 2025.0.111 2026-03-312026-03-312025-04-01falsedevelopment of diagnostic technology00truetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 14015776 2025-04-01 2026-03-31 14015776 2024-04-01 2025-03-31 14015776 2026-03-31 14015776 2025-03-31 14015776 c:Director2 2025-04-01 2026-03-31 14015776 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-04-01 2026-03-31 14015776 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2026-03-31 14015776 d:DevelopmentCostsCapitalisedDevelopmentExpenditure 2025-03-31 14015776 d:CurrentFinancialInstruments 2026-03-31 14015776 d:CurrentFinancialInstruments 2025-03-31 14015776 d:CurrentFinancialInstruments d:WithinOneYear 2026-03-31 14015776 d:CurrentFinancialInstruments d:WithinOneYear 2025-03-31 14015776 d:ShareCapital 2026-03-31 14015776 d:ShareCapital 2025-03-31 14015776 d:SharePremium 2026-03-31 14015776 d:SharePremium 2025-03-31 14015776 d:RetainedEarningsAccumulatedLosses 2026-03-31 14015776 d:RetainedEarningsAccumulatedLosses 2025-03-31 14015776 c:OrdinaryShareClass1 2025-04-01 2026-03-31 14015776 c:OrdinaryShareClass1 2026-03-31 14015776 c:OrdinaryShareClass1 2025-03-31 14015776 c:OrdinaryShareClass2 2025-04-01 2026-03-31 14015776 c:OrdinaryShareClass2 2026-03-31 14015776 c:OrdinaryShareClass2 2025-03-31 14015776 c:FRS102 2025-04-01 2026-03-31 14015776 c:AuditExempt-NoAccountantsReport 2025-04-01 2026-03-31 14015776 c:FullAccounts 2025-04-01 2026-03-31 14015776 c:PrivateLimitedCompanyLtd 2025-04-01 2026-03-31 14015776 d:DevelopmentCostsCapitalisedDevelopmentExpenditure d:InternallyGeneratedIntangibleAssets 2025-04-01 2026-03-31 14015776 e:PoundSterling 2025-04-01 2026-03-31 iso4217:GBP xbrli:shares xbrli:pure

Registered number: 14015776









PHOREST DIAGNOSTICS LTD







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MARCH 2026

 
PHOREST DIAGNOSTICS LTD
REGISTERED NUMBER: 14015776

BALANCE SHEET
AS AT 31 MARCH 2026

2026
2025
Note
£
£

FIXED ASSETS
  

Intangible assets
 4 
37,102
-

  
37,102
-

CURRENT ASSETS
  

Debtors: amounts falling due within one year
 5 
7,996
2,481

Cash at bank and in hand
  
13,933
56,862

  
21,929
59,343

Creditors: amounts falling due within one year
 6 
(50,598)
(5,239)

NET CURRENT (LIABILITIES)/ASSETS
  
 
 
(28,669)
 
 
54,104

TOTAL ASSETS LESS CURRENT LIABILITIES
  
8,433
54,104

  

NET ASSETS
  
8,433
54,104


CAPITAL AND RESERVES
  

Called up share capital 
 7 
11
11

Share premium account
  
250,003
250,003

Profit and loss account
  
(241,581)
(195,910)

  
8,433
54,104


Page 1

 
PHOREST DIAGNOSTICS LTD
REGISTERED NUMBER: 14015776
    
BALANCE SHEET (CONTINUED)
AS AT 31 MARCH 2026

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




Prof. T Krauss
Director

Date: 23 July 2026

The notes on pages 3 to 6 form part of these financial statements.

Page 2

 
PHOREST DIAGNOSTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

1.


GENERAL INFORMATION

Phorest Diagnostics Ltd is a private company limited by shares and incorporated in England and Wales. Its registered office is Department Of Physics, University Of York, Heslington, York, North Yorkshire, YO10 5DD.

2.ACCOUNTING POLICIES

 
2.1

BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

FOREIGN CURRENCY TRANSLATION

Functional and presentation currency

The Company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
2.3

RESEARCH AND DEVELOPMENT

In the research phase of an internal project it is not possible to demonstrate that the project will generate future economic benefits and hence all expenditure on research shall be recognised as an expense when it is incurred. Intangible assets are recognised from the development phase of a project if and only if certain specific criteria are met in order to demonstrate the asset will generate probable future economic benefits and that its cost can be reliably measured. The capitalised development costs are subsequently amortised on a straight-line basis over their useful economic lives of 5 years.

If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.

Page 3

 
PHOREST DIAGNOSTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

2.ACCOUNTING POLICIES (CONTINUED)

 
2.4

TAXATION

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

Deferred tax balances are recognised in respect of all timing differences that have originated but not reversed by the balance sheet date, except that:
The recognition of deferred tax assets is limited to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits; and
Any deferred tax balances are reversed if and when all conditions for retaining associated tax allowances have been met.

Deferred tax balances are not recognised in respect of permanent differences except in respect of business combinations, when deferred tax is recognised on the differences between the fair values of assets acquired and the future tax deductions available for them and the differences between the fair values of liabilities acquired and the amount that will be assessed for tax. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


 
2.5

INTANGIBLE ASSETS

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 The estimated useful lives range as follows:

Development expenditure
-
5
years

 
2.6

DEBTORS

Short-term debtors are measured at transaction price, less any impairment.

 
2.7

CASH AND CASH EQUIVALENTS

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.8

CREDITORS

Short-term creditors are measured at the transaction price.

Page 4

 
PHOREST DIAGNOSTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

3.


EMPLOYEES

The Company has no employees other than the directors, who did not receive any remuneration (2025 - £NIL).


4.


INTANGIBLE ASSETS




Development expenditure

£



COST


Additions
37,102



At 31 March 2026

37,102






NET BOOK VALUE



At 31 March 2026
37,102



At 31 March 2025
-


Page 5

 
PHOREST DIAGNOSTICS LTD
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2026

5.


DEBTORS

2026
2025
£
£


Other debtors
7,572
1,710

Prepayments and accrued income
424
771

7,996
2,481



6.


CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

2026
2025
£
£

Trade creditors
28,352
3,064

Other creditors
19,996
-

Accruals and deferred income
2,250
2,175

50,598
5,239



7.


SHARE CAPITAL

2026
2025
£
£
ALLOTTED, CALLED UP AND FULLY PAID



1,067,243 (2025 - 1,067,000) Ordinary shares of £0.00001 each
10.67
10.67
30,000 (2025 - 30,000) Deferred shares of £0.00001 each
0.30
0.30

10.97

10.97


 
Page 6